Cytogenetic action of 4'-epidoxorubicin (farmorubicin), an antitumor antibiotic was studied with using rat bone marrow cells. It was shown that after intraperitoneal administration the antibiotic increased the number of the aberrant metaphases when the dose was not lower than that equivalent to 1/30 of the LD50. The number of the aberrant metaphases increased with increasing of the antibiotic dose. The maximum number of the cells with impaired chromosomal apparatus was observed 6 hours after the antibiotic administration. In 72 hours it decreased to the level of spontaneous mutations in myelocariocytes. Cytogenetic activity of 4'-epidoxorubicin was comparable to that of doxorubicin (adriablastin) widely used in medical practice.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Identification of GBN5 as a molecular biomarker of pan-cancer species by integrated multi-omics analysis.
Discov Oncol
January 2025
Second Department of Oncology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei, China.
Introduction: We conducted a panoramic analysis of GBN5 expression and prognosis in 33 cancers, aiming to deepen the systematic understanding of GBN5 in cancer.
Materials And Methods: We employed a multi-omics approach, including transcriptomic, genomic, proteomic, single-cell cytomic, spatial transcriptomic, and genomic data, to explore the prognostic value and potential oncogenic mechanisms of GBN5 across pan-cancers from multiple perspectives.
Results: We found that GBN5 was differentially expressed in multiple tumors and showed early diagnostic value.
Mice with 16p11.2 Deletion and Duplication Show Alterations in Biological Processes Associated with White Matter.
Int J Mol Sci
January 2025
Neuroscience and Mental Health Innovation Institute, Cardiff University, Hadyn Ellis Building, Cardiff CF24 4HQ, UK.
Deletion and duplication in the human 16p11.2 chromosomal region are closely linked to neurodevelopmental disorders, specifically autism spectrum disorder. Data from neuroimaging studies suggest white matter microstructure aberrations across these conditions.
View Article and Find Full Text PDFMET Activation in Lung Cancer and Response to Targeted Therapies.
Cancers (Basel)
January 2025
Integrative Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.
The hepatocyte growth factor receptor (MET) is a receptor tyrosine kinase (RTK) that mediates the activity of a variety of downstream pathways upon its activation. These pathways regulate various physiological processes within the cell, including growth, survival, proliferation, and motility. Under normal physiological conditions, this allows MET to regulate various development and regenerative processes; however, mutations resulting in aberrant MET activity and the consequent dysregulation of downstream signaling can contribute to cellular pathophysiology.
View Article and Find Full Text PDFHigh Frequency of Alterations in Ovarian Cancers: Clinicopathological and Molecular Associations.
Cancers (Basel)
January 2025
Department of Cancer Pathomorphology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
Background: The phosphoinositide 3-kinase (PI3K) pathway is activated in multiple cancers. However, the significance of encoding the PI3K regulatory subunit, an inhibitor of the PI3K catalytic subunit encoded by , in ovarian cancer development is largely unknown.
Methods: Here, we investigated genomic alterations and gene expression by direct sequencing and qPCR methods in 197 ovarian cancers.
TGFBI regulates the TGF-β pathway to affect the malignant progression and cisplatin sensitivity in diffuse large B-cell lymphoma.
Ann Hematol
January 2025
Department of Hematology, The Third Affiliated Hospital of Wenzhou Medical University, NO. 108 Wansong Road, Wenzhou, 325200, China.
Despite the association between aberrant TGFBI expression and tumors development found in various cancer types, the role of TGFBI in diffuse large B-cell lymphoma (DLBCL) progression is not clear. This study attempted to reveal how TGFBI impacts malignant progression and cisplatin sensitivity in DLBCL. Bioinformatics and qRT-PCR were used to analyze expression of TGFBI.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!